- Microsoft Corp (NASDAQ:MSFT) developer platform GitHub laid off its entire engineering team in India virtually.
- Github has eliminated over 100 jobs in the South Asian market, TechCrunch reports citing familiar sources.
- GitHub notified the employees about the job cut on Tuesday.
- Also Read: Meta Prepares To Let 10K Employees Go, Flatten Organizational Structure, Cut Back On Non-Priority Projects
- Gergely Orosz, a former software engineer who runs a popular newsletter, Pragmatic Engineer, first tweeted about the downsizing.
- A GitHub spokesperson told TechCrunch that the layoff is part of its streamlining effort disclosed in February.
- GitHub said earlier that it would cut roughly 10% of its workforce by the quarter ending in March.
- In January, Microsoft confirmed it is reducing its headcount by roughly 10,000 employees, equating to 4% – 5% of the total headcount.
- Price Action: MSFT shares traded lower by 0.35% at $275.41 premarket on the last check Tuesday.
- Benzinga now provides actionable financial news and trading ideas for the Indian financial markets on in.benzinga.com.
Related Posts
These Are The Top Companies And Most Influential People In The Psychedelics Space: Meet The Winners Of The Microdose Awards
Which are the top companies and who are the most influential people in the psychedelics space?
According to Microdose Psychedelic Insights, host of the Microdose Awards, these are the ones to watch.
Rona Therapeutics Announced Exclusive Licensing Transaction from Sanofi for its Broad siRNA Therapeutic Portfolio and Technology Platform
Rona Therapeutics, Inc ("Rona"), a fully integrated platform company dedicated to the discovery, development and manufacturing of RNA therapeutics, today announced that it has obtained worldwide exclusive rights to Sanofi's siRNA platform of chemical modification and delivery moiety as well as rights to four pre-clinical candidates for undisclosed targets.
UBS Maintains Buy on Linde, Raises Price Target to $410
UBS analyst Geoff Haire maintains Linde (NYSE:LIN) with a Buy and raises the price target from $375 to $410.